More intriguing is that recent research suggests that the combination of PPAR-γ agonists with platinum based chemotherapy are synergistic in treating NSCLC in vitro for human NSCLC and in vivo in murine models. This evidence concerns the gene PPARG and non-small cell lung carcinoma.